(2809) Trilogy 100
Payments companies reported to CMS as associated with (2809) Trilogy 100. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with (2809) Trilogy 100, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with (2809) Trilogy 100
These are the largest totals companies reported as associated with (2809) Trilogy 100. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Philip Choi | Ann Arbor, MI | Pulmonary Disease | $23,155.89 |
| John Hansen-Flaschen | Philadelphia, PA | Pulmonary Disease | $18,625.48 |
| Allison Tobey | Pittsburgh, PA | Otolaryngology | $305.75 |
| Myat Han | Sioux Falls, SD | Hospitalist | $14.29 |
| Sunil Parkash | Williamsport, PA | Internal Medicine | $14.29 |
| Jacob Kashani | Long Island City, NY | Internal Medicine | $14.29 |
| Uma Gupta | Columbus, OH | Pediatrics | $14.29 |
| Hemamalini Sakthivel | Brooklyn, NY | Internal Medicine | $14.29 |
| Sushma Edara | Dayton, OH | Internal Medicine | $14.29 |
| Widz Douillard | Hartford, CT | Internal Medicine | $14.28 |
Prescribed (2809) Trilogy 100?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.